Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. MSTR
7. HOOD
8. ABBV
9. DFTX
10. RGNX

Go back to Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing

FDA Panel Points to Narrower Label for Amgen's (AMGN) Repatha, Nomura Notes

June 11, 2015 8:31 AM EDT

Nomura Securities analyst M. Ian Somaiya maintained his Buy rating and $182 price target on Amgen (NASDAQ: AMGN) following FDA panel recommendation for Repatha but notes commentary points to a narrower label.

Somaiya commented, "We believe the recent FDA Advisory Committee panels... More

Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia

June 11, 2015 7:13 AM EDT

Cowen analyst Eric Schmidt reiterating an Outperform rating and $189 price target on Amgen (NASDAQ: AMGN) after an FDA panel backed Repatha in familial hypercholesterolemia.

Analyst Erich Schmidt commented, "The FDA's EMDAC panel recommended Repatha be approved for HoFH (15:0 vote) and one more additional very... More

UPDATE: Amgen (AMGN) Wins FDA Panel Backing for Repatha

June 10, 2015 3:57 PM EDT

(Updated - June 10, 2015 4:26 PM EDT)

An FDA panel voted 11-4 to back Amgen's (NASDAQ: AMGN) Repatha in some patients. The panel also backed the drug for HoFH with a vote of 15-0.

Repatha is an investigational fully human monoclonal antibody that inhibits... More